Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

HNSCC Clinical Trial

— SANTAL  

Official title:

A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02998385
• Other study ID #: GORTEC 2016-02
• Status: Recruiting
• Phase: Phase 3
• Start date: January 20, 2017
• Est. completion date: March 2030

Study information

• Verified date: September 2023
• Source: Groupe Oncologie Radiotherapie Tete et Cou
• Contact: François Régis FERRAND, MD
• Phone: +33 1 78 65 12 49
• Email: francoisregis.ferrand[@]gustaveroussy.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase III, multicenter, randomized, open-label, french study comparing: - Arm A : Radiotherapy alone (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction) (IMRT or protontherapy) - Arm B: Radiotherapy (66 to 70 Gy; 5 fractions/week; 1fraction/day; 2 Gy/fraction; IMRT or protontherapy) + concomitant cisplatin 100 mg/m2 IV on day 1 - J22 - 43 (3 cycles)

Description:

Carcinomas of the sinuses and the salivary glands are rare. They are heterogeneous in terms of anatomical sites and histology subtypes. For this reason and in the absence of prospective study, their treatment is still largely extrapolated from data of frequent carcinomas of the upper digestive tract. These tumors are most often diagnosed lately. Their treatment is based on a multimodal management of care, with a central place for the surgery and radiotherapy (Proof level Grade C). Despite the advances in surgical techniques, and the addition of radiation therapy, the 5-year overall survival probability does not exceed 65% mainly due to a loco regional development. In this context, a chemotherapy administered concomitantly to radiotherapy, could increase the efficacy of the locoregional treatment by a radiosensibilization process and regardless of the histology. This point is regularly discussed in multidisciplinary concertation meeting, including bi-monthly national REFCOR meeting (network of French Expertise on rare Cancers of the head and neck). At present, the lack of data brings even to discuss the addition of cisplatin to exclusive irradiation of unresectable or not operable tumors. No randomized study has been published in this context. The first comparative prospective study addressing the addition of weekly cisplatin to the adjuvant irradiation of salivary, is a phase II randomized study (Radiation Therapy Oncology Group - RTOG 1008) currently enrolling patients in the United States of America. The Sponsor propose to conduct a phase III randomized study evaluating the impact of the addition of cisplatin to a treatment by radiotherapy in adjuvant setting (≥ 65 Gy) in case of a high risk of recurrence: case of radioresistant histologies (e.g. cystic fibrosis adenoids carcinomas), or case of unfavourable histo-prognostic criteria (incomplete resection, presence of emboli, etc.) in this population.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 342
• Est. completion date: March 2030
• Est. primary completion date: February 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Resected tumors of the sinus or the salivary glands T3-4, N1-3 or T1-2 N0, with overgrown banks or positive margins (< 5 mm) or Unresectable or not operable tumors of salivary glands or sinuses
• Carcinomas of the main salivary glands (parotid, submandibular or sublingual glands) and accessories or Malignant sinus tumors with any histological type except melanoma, lymphoma, mesenchymal tumor (sarcoma type), squamous cell carcinoma and nasopharyngeal carcinoma type 1, 2, 3.
• Age = 18 years
• Performance status 0 -2 (WHO criteria)
• For patients = 70 years, the score to the G8 questionnaire must be > 14 with no fall in the previous 12 months or with a geriatric assessment consistent with the administration of chemotherapy
• Estimated life expectancy greater than or equal to 6 months
• Neutrophils > 1.5 x 109/l, platelets > 100 x 109/l, hemoglobin = 9.5 g/dl, bilirubin = 3 x upper normal value (ULN), AST/ALT < 5 ULN, PAL < 3 ULN
• Creatinin Clearance = 60 mL/min (Cockroft formula)
• Adequate cardiac function according to the investigator, compatible with the administration of cisplatin 100 mg/m²
• Affiliation to a social insurance or beneficiary of such a regimen
• Patient having given his written consent signed before any study specific procedure.

Exclusion Criteria:

• History of radiotherapy in the ENT region and/or neoadjuvant chemotherapy for the pathology concerned
• Synchronous metastases
• Contraindications for administration of cisplatin or carboplatin
• Allergy to cisplatin and/or its excipients
• Vaccination against yellow fever, recent or planned
• Administration of phenytoin with prophylactic purpose
• Other cancer, except for cancer in situ of the cervix, skin Carcinoma (except melanoma) or cancer controlled for more than 5 years
• Pregnant, breastfeeding or without birth control woman. Woman having the ability to procreate should have (serum or urinary) negative pregnancy test within 14 days prior to study treatment decision-making. (Men or women) patients should use a reliable contraceptive method throughout the treatment and at least 6 months after the end of chemotherapy.
• Persons deprived of liberty under supervision or under curatorship, or unable to adhere to medical follow-up of the study for geographical, social or psychological reasons.

Related Conditions & MeSH terms

• HNSCC
• Nose Neoplasms

Intervention

Drug:
• Cisplatin
intravenous, concomitant to irradiation

Radiation:
• radiotherapy
66 à 70 Gy per fractions of 2 Gy, 1 fraction/day, 5 fractions/week

Locations

Country	Name	City	State
France	Hôpital Bégin	Saint-Mandé

Sponsors (2)

Lead Sponsor	Collaborator
Groupe Oncologie Radiotherapie Tete et Cou	National Cancer Institute, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of quality of Life: QLQC30 overall score	Compare quality of life (QLQC30 overall score) between arms	From date of randomization to end of study or death or progression (the first occurred), assessed during 62 months
Primary	Progression-free survival	Compare progression-free survival between the 2 treatment arms: radiation therapy alone versus radiochimiotherapy in adjuvant patients treatment operated.	From date of randomization to date of disease progression or death, which occur first, assessed during 62 months
Secondary	Overall Survival	Compare the 2 arms of treatment in operated patients in terms of overall survival	From date of randomization to date of death, assessed during 62 months